Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04125784
Other study ID # V2_02082019
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 1, 2021
Est. completion date February 28, 2023

Study information

Verified date March 2023
Source Medical University of Vienna
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Traditional risk factors for cardiovascular diseases have been shown to have an even higher impact in the HIV infected population. The original study from 2014 was a cross sectional study into the prevalence of cardiovascular risk factors (namely, dyslipidaemia and diabetes mellitus) in people living with HIV (PLWHIV) in Austria. The aim of this follow up study is to see the progression of our study sample and to see what prevalence levels may be found after 7 years. This epidemiological evaluation is conceptualized to document real life major cardiovascular risk factors of HIV-infected patients, focusing on lipid profiles and diabetes mellitus risk and to compare with the baseline values from the original study.


Description:

Background: In developed countries, an increase in cardiovascular events and related mortality has been seen; even more prominent in people living with HIV (PLWHIV) as compared to non-HIV control groups. Studies have shown dyslipidaemia and diabetes mellitus type 2 as important risk factors for cardiovascular diseases in PLWHIV. The original study by this group in 2014 was a cross sectional study into the prevalence of cardiovascular risk factors (dyslipidaemia and diabetes mellitus) in PLWHIV in Austria and identified characteristics associated with these two risk factors. In that previous study dyslipidaemia was diagnosed in 46.3% of cases and half of all the study participants showed an increased insulin resistance. Eight persons (1.6%) fulfilled the criteria for diabetes mellitus type 2. Purpose: The aim of this follow up study is to see the progression of our study sample and to see what prevalence levels may be found after 7 years. Additionally, a look into previously identified characteristics associated with dyslipidaemia and diabetes mellitus type may provide valuable insight into the temporal effects. Finally, examining resource use this population in terms of medications can provide insights into current practice and its associated costs in Austria, as well as an estimate of the added medication cost of dyslipidaemia and diabetes mellitus type 2 in this population. It is our aim to close the existing knowledge gap on the role of dyslipidaemia and diabetes mellitus on cardiovascular risk among PLWHIV in Austria. Therefore, the investigation will be carried out by using routine data within minimum additional effort to the study team. The data obtained may serve as a base for future decisions on treatment of the Austrian HIV population. Study details: Our epidemiologic evaluation documents real life major cardiovascular risk factors of HIV-infected patients, focusing on lipid profiles and diabetes mellitus risk. The gathered data from approximately 450 originally enrolled patients will be compared with the baseline values analysed in the original study in 2014. Data collection: Dataset definitions and the minimum dataset will be determined by the study authors. Parameters used and documented must match those that were taken in the original study. These were specified in the case report form (CRF). The data collection and preparation will be done by a student of the Medical University of Vienna (Department of Social and Preventive Medicine) as a part of the graduate thesis. Enrolment Strategy: Patients will be recruited through the original study sites (2 extramural HIV clinics in Vienna). Original patient lists will be screened through the official Mortality Register of the Statistics Austria, where patients who have died during the follow up period will be identified. Additionally, other patients who decline participation will be asked to give reasons of declining participation. Data Validation and Data quality: Accurate data are crucial contributors to informative statistical analyses. Missing data will not be systematized. Quality Control: Source documentation and data accuracy will be verified by site visit(s) in 1 randomly selected site after termination of the enrolment period. 10% of case report forms of the reviewed site will be randomly selected for monitoring.


Recruitment information / eligibility

Status Completed
Enrollment 450
Est. completion date February 28, 2023
Est. primary completion date December 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Only Participants who participated in the previous study - Adult (older than 18 years) - male and female patients diagnosed and confirmed HIV diagnosis, given written informed consent Exclusion Criteria: - No participation in the original study

Study Design


Locations

Country Name City State
Austria Schalk:Pichler Gruppenpraxis Vienna

Sponsors (2)

Lead Sponsor Collaborator
Moritz Oberndorfer Merck Gesellschaft mbH, Austria

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in dyslipidemia prevalence from baseline - total cholesterol Total cholesterol values will be analyzed by an authorized laboratory 7 years
Primary Changes in dyslipidemia prevalence from baseline- triglycerides Triglyceride values will be analyzed by an authorized laboratory 7 years
Primary Changes in dyslipidemia prevalence from baseline - HDL-cholesterol HDL-Cholesterol values will be analyzed by an authorized laboratory 7 years
Primary Changes in dyslipidemia prevalence from baseline - Apolipoprotein B Apolipoprotein B values will be analyzed by an authorized laboratory 7 years
Primary Changes in dyslipidemia prevalence from baseline - LDL-cholesterol a. LDL will be calculated using the Friedewald formula. As the Friedewald formula does not work in case of triglycerides > 300, in these patients only non-HDL-C will be used. 7 years
Primary Changes in dyslipidemia prevalence from baseline - Non-HDL-Cholesterol Non-HDL-Cholesterol will be calculated additionally. 7 years
Primary Changes from baseline in diabetes mellitus type II prevalence The diabetes mellitus prevalence will be assessed through patient history (checking for a diabetes mellitus type II diagnosis since baseline) 7 years
Secondary Description of risk profile for cardiovascular events in the sample population The cardiovascular risk will be assessed through the European Society of Cardiology (ESC) calculator. Therefore, the risk profile for cardiovascular events will be assessed through documentation of risk factors (sex, age, smoking status, history of diabetes, hypertension, dyslipidaemia, previous cardiovascular events, other comorbidities) and laboratory parameters on the CRF by the investigator. at follow up recruitment, Day 0
Secondary Changes from baseline in drug utilization for PLWHIV Drug utilization will be assessed through documentation on the CRF by the investigator 7 years
Secondary Prevalence of diabetes mellitus type 2 in correlation to the prescribed antiretroviral regime during the follow up time Diabetes mellitus type 2 will be assessed from patient history 7 years
Secondary Changes from baseline in the lipid profile of patients in correlation to prescribed antiretroviral regime Lipid profile will be assessed with laboratory parameters (total cholesterol, triglycerides, HDL, Apolipoprotein B). LDL will be calculated using the Friedewald formula, additionally, non-HDL-Cholesterol (Non-HDL-C) will be calculated . As the Friedewald formula does not work in case of triglycerides > 300, in these patients only Non-HDL-C will be used. 7 years
Secondary Changes from baseline in therapy prescriptions of patients who were found to have hyperlipidaemia during first study in 2014 Therapy prescriptions will be assessed through documentation of the patient's medication on the CRF by the investigator. 7 years
Secondary Documentation of any major cardiovascular events (stroke or heart attack) Cardiovascular events (stroke or heart attack) will be assessed through documentation on the CRF by the investigator. during 7 years
Secondary Incidence of diabetes mellitus type 2 in patients who were diagnosed found to be insulin resistant in the first study in 2014 Self reported diagnosis or presence of diabetes type 2 medication as noted in the CRF 7 years
Secondary Changes from baseline in therapeutic regimes within those patients who were identified as having diabetes mellitus type 2 in the first study in 2014 Therapeutic regimes will be assessed through documentation of the patient's medication on the CRF by the investigator. 7 years
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2